Conference Coverage
Conference Coverage
Potential cause of worse outcomes among Black breast cancer patients found
Tumor microenvironment of metastasis doorways predicted worse outcomes in Black women with residual ER+/HER2– cancer after neoadjuvant...
News
Deductibles a threat to more imaging after abnormal mammogram
The ACA does not mandate coverage for additional tests and a biopsy to help determine whether the patient has cancer.
Conference Coverage
Whole breast radiation for breast cancer shown to be safe and effective
Whole breast radiation can cut treatment time from 6 weeks down to 3 weeks.
Conference Coverage
Personalized breast screening a step closer to reality
“Several breast cancer risk prediction models have been created, but we believe this is one of the first models designed to guide breast screening...
Conference Coverage
Novel vaccine approach halts disease after 23 years of breast cancer
“The biggest impact so far for me has been that, for the first time in more than a decade, I am not on any medication. That’s really amazing.”
Conference Coverage
How AI is, or will soon be, relevant in radiation oncology
Radiation oncologists at ASTRO 2022 discuss practical applications of AI, and new research findings.
Conference Coverage
Findings may be practice changing for early breast cancer patients
A radiation boost to the tumor bed during whole breast irradiation was as safe and effective as delivering the boost sequentially.
Conference Coverage
What is known about sexual dysfunction after breast cancer?
Sexual dysfunction often predates the cancer diagnosis and doesn’t improve but rather worsens in the following 2 years.
Conference Coverage
High BMI linked to better survival for cancer patients treated with ICI, but for men only
The reasons behind the findings and implications for treatment are unknown, as is whether it applies to patients with specific cancers.
Conference Coverage
A farewell to arms? Drug approvals based on single-arm trials can be flawed
Objective responses, not time-dependent survival outcomes, should be endpoints for single-arm trials, with results only used for conditional...